Oren Miller, MD
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 59 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $552, 9.2 times the $60 reported in 2019. That places this record below the midpoint for urology clinicians in OK, where the typical reported total is $3,895.
Across 59 payments — averaging $22.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$291
- Bayer$142
- Dendreon Pharmaceuticals LLC$87
- E.r. Squibb & Sons, L.L.C.$75
- Antares Pharma, Inc.$64
- Accord Healthcare, Inc.$58
- plus $600 from 19 others
What the payments were for
- Food & beverage$1,317100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 11 | $291 |
| Bayer | 5 | $142 |
| Dendreon Pharmaceuticals LLC | 4 | $87 |
| E.r. Squibb & Sons, L.L.C. | 4 | $75 |
| Antares Pharma, Inc. | 4 | $64 |
| Accord Healthcare, Inc. | 3 | $58 |
| Pfizer | 2 | $54 |
| Olympus America Inc. | 2 | $48 |
| Merck | 2 | $46 |
| Novo Nordisk | 2 | $43 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| AbbVie | 2 | $36 |
| Verity Pharmaceuticals Inc. | 2 | $36 |
| Coloplast | 2 | $36 |
| Immunitybio, Inc. | 1 | $34 |
| Boston Scientific | 1 | $29 |
| Caris MPI, Inc. | 1 | $29 |
| Zyla Life Sciences, Inc. | 2 | $27 |
| Tolmar, Inc. | 1 | $24 |
| Ferring Pharmaceuticals Inc. | 1 | $23 |
| Telix Pharmaceuticals | 1 | $21 |
| Blue Earth Diagnostics | 1 | $20 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Amgen | 1 | $17 |
| Palette Life Sciences, Inc. | 1 | $16 |
How this compares
$1,317 in reported general payments places this provider in the 35th percentile of 145 urology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Solifenacin Succinate | 12 | $68 |
Paid to pharmacies, not to this prescriber.
Other urology in Tulsa
- Melanie KetchandjiTulsa$111K
- Marc MilstenTulsa$29K
- Scott LitwillerTulsa$27K
- Charles PritchardTulsa$23K
- Sean DoyleTulsa$17K
- Joshua VicenaTulsa$16K
- Curtis PowellTulsa$16K
- Wesley BrookoverTulsa$13K
- Thomas RashidTulsa$12K
- Dae KimTulsa$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.